Supplementary Materials

The modified 6-chromanol SUL-238 protects against accelerated vascular aging in vascular smooth muscle *Ercc1*-deficient mice

Annika A. Jüttner[1], Soroush Mohammadi Jouabadi[1], Janette van der Linden[1,2], Rene de Vries[1], Sander Barnhoorn[2], Ingrid M. Garrelds[1], Yoëlle Goos[1,3], Richard van Veghel[1], Ingrid van der Pluijm[2,4], A. H. Jan Danser[1], Pier G. Mastroberardino[2,5,6], Adrianus C. van der Graaf[7], Daniël H. Swart[7,8], Robert H. Henning[8], Jenny A. Visser[9], Guido Krenning[7,8], Anton J. M. Roks[1]

[1]Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, the Netherlands.

[2]Department of Molecular Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, the Netherlands.

[3]Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam 3015 GD, the Netherlands.

[4]Department of Vascular Surgery, Cardiovascular Institute, Erasmus University Medical Center, Rotterdam 3015 GD, the Netherlands.

[5]IFOM-ETS, the AIRC Institute for molecular Oncology, Milan 20139, Italy.

[6]Università degli Studi dell'Aquila, L'Aquila 67100, Italy.

[7]Sulfateq B.V., Groningen 9726 GN, the Netherlands.

[8]Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen 9713 AV, the Netherlands.

[9]Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, the Netherlands.

Correspondence to: Dr. Anton J. M. Roks, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Rotterdam 3015 CN, the Netherlands. E-mail: a.roks@erasmusmc.nl

Supplementary Table 1. Primer sequences from primers used for qPCR

Primer	Sequence
ccl2 forward	AGCTGTAGTTTTTGTCACCAAGC
ccl2 reverse	TGTCTGGACCCATTCCTTCTTG
il1β forward	ATGCCACCTTTTGACAGTGATG
il1β reverse	GCAGCCCTTCATCTTTTGGG
il6 forward	TCCAGTTGCCTTCTTGGGAC
il6 reverse	GTGTAATTAAGCCTCCGACTTG
kim-1 forward	CAAACCAGACTGGAATGGCA
kim-1 reverse	CTGGAGGGATTGCTTCAGTGT
ngal forward	GGAACGTTTCACCCGCTTTG
ngal reverse	CCACACTCACCACCCATTCA
p21 forward	CAGACCAGCCTGACAGATTTC
p21 reverse	GTTTTCTCTTGCAGAAGACCAATCT
β-actin forward	CACTGTCGAGTCGCGTCC
β-actin reverse	TCATCCATGGCGAACTGGTG
gapdh forward	GTGCAGTGCCAGCCTCGT
gapdh reverse	GAAGGGGTCGTTGATGGCAA

Supplementary Figure 1. Representative pictures of Sirius red (A) and Von Gieson stain (B) in carotid arteries. Assessment of changes in matrix metalloprotease after injection of MMPsense680™ (C), evaluation of protein abundances of MMP2 (D) and MMP9 (E) in abdominal aorta, and corresponding blot images (F). Unpaired *t*-test (C) and 2-way ANOVA (D, E) with $P < 0.05$.

Supplementary Figure 2. Representative pictures of TUNEL stain in thoracic aorta (A). Apoptosis assessment in aorta after injecting Annexin-Vivo750™ (B), CD31 immunofluorescence stain in carotid arteries and representative pictures (C, D). P21 (E) and RUNX2 (F) immunohistochemical staining in aortic arch and corresponding pictures. Unpaired *t*-test (B, E, F) and 2-way ANOVA (D) with *P* < 0.05 and *significant effect of the genotype.